Dr. Reddy's, MediCane Launch Medical Cannabis Products In Germany; To Fund Cannabis Trial

Indian drug maker Dr. Reddy's Laboratories Ltd. (DRREDDY) and MediCane Health Inc., announced the launch of their medical cannabis products supply in Germany. In addition, the two parties have also inked a deal for the co-funding of a phase II clinical trial for a cannabis product.

With the move, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with necessary logistic and regulatory support.

As the exclusive distributor of the products in Germany, Dr. Reddy's will provide access to MediCane's medical cannabis products under its own brand.

Patrick Aghanian, Head of European Generics at Dr. Reddy's, said: "This collaboration with MediCane Health demonstrates Dr. Reddy's commitment to take a leadership position in Europe's rapidly growing medical cannabis market. With MediCane, we join forces with a unique and differentiated research-based partner in the medical cannabis field..."

The move to distribute medical cannabis products in Germany, which represents over half of the current EU medical cannabis market, follows a partnership agreed between the two firms last year.
The agreement for the co-funding of a phase II clinical trial for a cannabis product is aimed at symptom relief of Behavioral and Psychological Symptoms of Dementia (BPSD).

Accordingly, Dr. Reddy's will hold exclusive sales and marketing rights for such a product in Europe, except Russia and CIS countries, upon completion of the trial.

The companies expect to commence the clinical trial of the product during the second half of 2022.

BPSD refers to the spectrum of commonly observed non-cognitive and non-neurological symptoms of dementia, such as agitation, aggression, psychosis, depression, and apathy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT